Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

PathAI presents data on using AI to aid liver research and NASH drug development

By Brian Buntz | November 4, 2022

PathAIPathology-focused AI company PathAI will present findings on the use of machine learning (ML) to enhance the scoring of nonalcoholic steatohepatitis (NASH) at the 2022 AASLD 2022 Liver Meeting.

The AASLD 2022 Liver Meeting is Nov. 4–8 in Washington, D.C., where the  company will share five presentations. Boston-based PathAI developed four of them with pharmaceutical collaborators. 

An oral presentation jointly developed with Gilead Sciences (Nasdaq:GILD) will touch on using exploratory analyses of NASH histology with CRN scores informed by a multi-stain ML technique. The companies will explain how a new ML-based scoring model pulling data from images stained with hematoxylin and eosin (H&E) and Masson’s Trichrome can predict NASH CRN grades and stages. 

According to the presenters, the new technique has potential to reduce the high variability found in the current evaluation process of NASH biopsies. The method incorporates data from multiple hole-slide images to predict NASH CRN grades and stages on a continuous scale. 

Furthermore, the continuous CRN feature scores that were extracted from these predictions were derived from the same input; as such, the PathAI model allows for a direct comparison between features associated with all four NASH histological features, revealing biologically meaningful correlations between model-derived scores and both non-invasive metrics of liver disease and gene expression patterns.

PathAI will also present two sessions in collaboration with Novo Nordisk (NYSE:NVO). The first will compare the effects of the glucagon-like peptide 1 receptor agonist semaglutide on liver histology in patients with NASH cirrhosis in an ML model assessment versus pathologist evaluation. In the second session co-presented with Novo Nordisk, PathAI will explore the association between improvement in ML-assessed steatosis area and MRI-proton density fat fraction in patients with compensated nonalcoholic steatohepatitis cirrhosis. 

PathAI will join the clinical-stage biopharma 89Bio to talk about variability in liver biopsy assessment using data from a Phase 1b/2a NASH study. 

“The latest research from our team aimed to explore the variabilities that exist in pathologist review of liver biopsies,” PathAI Chief Scientific Officer Dr. Mike Montalto said in a news release. “Our findings indicate that integrating artificial intelligence solutions into this process can greatly enhance the consistency and accuracy of these assessments.”

Earlier this year, we profiled Beacon Biosignals, which is using ML to tap insights from EEG data for drug development.


Filed Under: Hepatology
Tagged With: PathAI
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Human Internal Digestive Organ Liver Anatomy
GLP-1 drugs could open a new frontier in NASH treatment
OrsoBio
Beyond GLP-1: OrsoBio targets mitochondria to treat metabolic disorders from a new and potentially complementary angle
A nurse-turned-pharma-exec strives to advance care for those with an autoimmune liver disease
Arrowhead/GSK
GSK could pay Arrowhead $1B to develop NASH RNAi therapeutic 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE